BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California. Show more
10255 Science Center Drive, San Diego, CA, 92121, United States
Market Cap
851.8M
52 Wk Range
$15.25 - $27.99
Previous Close
$26.80
Open
$26.37
Volume
246,865
Day Range
$25.03 - $27.31
Enterprise Value
779.2M
Cash
95.38M
Avg Qtr Burn
-23.23M
Insider Ownership
12.71%
Institutional Own.
26.16%
Qtr Updated
06/30/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
BH-30643 (EGFR Inhibitor) Details C797S-Positive Resistance In EGFR-Mutant Non-Small Cell Lung Cancer | Phase 1/2 Update |